Clinical Study
Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases
Table 8
Clinical studies of intrathecal non-MSCs stem cells described in the literature.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbreviations: CP, cerebral palsy; MD, muscular dystrophy; SCI, spinal cord injury. Included (no. of patients): paraplegia (42), ataxia (23), multiple sclerosis (19), amyotrophic lateral sclerosis (12), sequelae of cerebrovascular diseases (6), multiple system atrophy (4), motor neuron disease (2), cerebral palsy (1), nerve injury (brachial plexus) (1), traumatic brain injury sequelae (1), hypoxic-ischaemic encephalopathy sequelae (1), cervical spondylotic myelopathy (1), and optic nerve hypoplasia (1). Auto: autologous; AC: aspirate concentrate; BM: bone marrow; CBMCs: cord blood mononuclear cells; HSCs: haematopoietic stem cells; MCs: mononuclear cells; PCs: progenitor cells; SCs: stem cells; UCMSCs: umbilical cord mesenchymal stem cells. |